| Literature DB >> 18440674 |
Walter Jaoko1, Frederick N Nakwagala, Omu Anzala, Gloria Omosa Manyonyi, Josephine Birungi, Annet Nanvubya, Farah Bashir, Kirana Bhatt, Hilda Ogutu, Sabina Wakasiaka, Lucy Matu, Wambui Waruingi, Jane Odada, Micah Oyaro, Jackton Indangasi, Jeckonia Ndinya-Achola, Carol Konde, Emmanuel Mugisha, Patricia Fast, Claudia Schmidt, Jill Gilmour, Tony Tarragona, Carol Smith, Burc Barin, Len Dally, Bruce Johnson, Andrew Muluubya, Leslie Nielsen, Peter Hayes, Mark Boaz, Peter Hughes, Tomás Hanke, Andrew McMichael, Job Bwayo, Pontiano Kaleebu.
Abstract
The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-gamma) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18440674 DOI： 10.1016/j.vaccine.2008.02.071
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641